Jazz Pharmaceuticals announced that the National Institute for Health and Care Excellence has published a Final Appraisal Determination recommending Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion for routine use on the National Health Service in England and Wales for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia or AML with myelodysplasia-related changes – two types of secondary AML.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.